Return to homepagePandemic Pact

Investigating COVID-19 infectiousness and antibody evolution in COVID-19 patients in SSA and Europe

  • Funded by European & Developing Countries Clinical Trials Partnership (EDCTP)
  • Total publications:21 publications

Grant number: RIA2020EF-3008

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $499,605.12

  • Funder

    European & Developing Countries Clinical Trials Partnership (EDCTP)

  • Principal Investigator

    Dr. Julie Fox

  • Research Location

    Uganda, South Africa

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The COVAB project (RIA2020EF-3008) aims to understand antibody evolution following exposure to and/or SARS-CoV-2 infection, and to investigate factors associated with infection by SARS-CoV-2 across oral and nasal mucosa biopsies.

Publicationslinked via Europe PMC

Last Updated:an hour ago

View all publications at Europe PMC

The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort.

The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies.

Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations.

An Optimised Indirect ELISA Protocol for Detection and Quantification of Anti-viral Antibodies in Human Plasma or Serum: A Case Study Using SARS-CoV-2.

The Distinct Absence of a Post-boost Spike-IgG Antibody Surge in Ugandan Recipients of the Pfizer-BioNTech Vaccine Has Implications for Vaccination Policies

Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection.

Evaluation of a human mucosal tissue explant model for SARS-CoV-2 replication.

Proteomic Analysis of Mucosal and Systemic Responses to SARS-CoV-2 Antigen.

Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.